ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) Price / Book
- 2026-09-03: Price/Book Ratio 13.49.
- 2026-06-30: Price/Book Ratio 14.93.
- 2026-03-31: Price/Book Ratio 15.53.
- 2025-12-31: Price/Book Ratio 18.9.
Historical market capitalization divided by filed shareholder equity.
- Available history
- 2020-03-31 to 2026-09-03
- Data captured
Historical Price/Book Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |